|
gptkbp:instanceOf
|
gptkb:chemical_compound
antiviral drug
|
|
gptkbp:affiliatedWith
|
gptkb:4-aminoquinoline
|
|
gptkbp:ATCCode
|
gptkb:P01BF05
|
|
gptkbp:CASNumber
|
4085-31-8
|
|
gptkbp:combines
|
gptkb:dihydroartemisinin
|
|
gptkbp:contraindication
|
prolonged QT interval
|
|
gptkbp:developedBy
|
gptkb:China
|
|
gptkbp:discoveredIn
|
1960s
|
|
gptkbp:eliminationHalfLife
|
20–30 days
|
|
gptkbp:excretion
|
feces
|
|
gptkbp:hasMolecularFormula
|
C29H32Cl2N6
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
piperaquine
|
|
gptkbp:IUPACName
|
gptkb:1,3-bis[1-(7-chloroquinolin-4-yl)-1,4-piperazinyl]propane
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits heme detoxification in Plasmodium
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
535.51 g/mol
|
|
gptkbp:partOf
|
artemisinin-based combination therapy
|
|
gptkbp:pregnancyCategory
|
gptkb:C_(Australia)
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL2104746
21106313
54680690
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
QT prolongation
gastrointestinal disturbances
|
|
gptkbp:synonym
|
gptkb:piperaquine_phosphate
gptkb:piperaquine_tetraphosphate
|
|
gptkbp:UNII
|
8E1G84046X
|
|
gptkbp:usedFor
|
treatment of malaria
|
|
gptkbp:bfsParent
|
gptkb:dihydroartemisinin
|
|
gptkbp:bfsLayer
|
6
|